We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to transmit to future generations a world that can ensure access to quality health care for all.

Operating in 150 countries, we have 22,000 employes worldwide and a revenue of 4.615 billion euros in 2019. Entirely independent, we invest each year an average of 25% of our total revenue (excluding generic activities) into Research and Development, and all profits are used for further development.

Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes. We are a leading force in cardiology—number 2 in Europe, number 6 worldwide—and we aim to become a recognized player in oncology; we also manufacture high-quality generic medicines.

Our three research centers are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 16 production centers around the world. 98% of Servier medicines active ingredients are synthesized in its own plant in Bolbec-Baclair in France. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth TM Digital Medicine initiative.

All our employees are driven by shared Values ​​and guided by a common Vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs.

With 100 million of patients treated each day worldwide by our medicinal products, we are keenly aware of our responsibilities to patients, doctors and health care professionals. They are the motivating force behind our daily drive for innovation as a provider of therapeutic progress.